Beyondspring, Inc. · NASDAQ:BYSI

Beyondspring — Technical Presentation (December 2025)

9 slides from Beyondspring's technical presentation, Dec 6, 2025

  1. Slide 1: Plinabulin/Docetaxel vs. Docetaxel in 2L/3L EGFR WT NSCLC (DUBLIN-3) Asian subset

    Plinabulin/Docetaxel vs. Docetaxel in 2L/3L EGFR WT NSCLC after Platinum Regimens (DUBLIN-3): a Phase 3 Randomized Controlled Trial Asian subset (n=488) Dr. Baohui Han, Shanghai Chest Hospital 6 Dec. 2025

  2. Slide 2: Declaration of Interests

    DECLARATION OF INTERESTS Dr. Baohui Han BeyondSpring, Eli Lilly, AstraZeneca, Merck, and Chia Tai Tianqing Pharma Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.

  3. Slide 3: Unmet Medical Needs in 2/3L NSCLC, EGFR WT

    Unmet Medical Needs in 2/3L NSCLC, EGFR WT Docetaxel remains SOC with limited benefit Docetaxel Overview Industry-wide Phase 3 Trials Summary • Approved >25 years ago • 7 global trials including ADCs and anti-PD-(L)1 combos did not • Remains the NCCN-recommended standard of care for 2L/3L improve OS

  4. Slide 4: Plinabulin Mechanism in Dendritic Cell Maturation

    Plinabulin Mechanism in Dendritic Cell Maturation As a Unique Tubulin Binder, Plinabulin monohydrate (small molecule, NCE) Effectively Liberates GEF-H1 from Microtubules Leading to DC Maturation and T-cell Activation 2 Kashyap et al., Cell Reports 28(13): 3367-3380 (2019) Plinabulin-Responding Patie

  5. Slide 5: DUBLIN-3 Study Design

    DUBLIN-3 Study Design Plinabulin + Docetaxel vs Docetaxel in 2/3L NSCLC, EGFR WT Balanced Baseline Characteristics (Asian Subset) Docetaxel + placebo (D group) Docetaxel + plinabulin (DP group) Characteristics Study Design Median age, years (range) N=245 59.0(25.0-78.0) N=243 61.0(37.0-76.0) <65 169

  6. Slide 6: DUBLIN-3 Study Asian Subset Primary Endpoint (OS)

    DUBLIN-3 Study Asian Subset Primary Endpoint (OS) Plinabulin/Docetaxel Met its Primary Endpoint (OS) with Significant Improvement in Long-term OS Rate; More Pronounced OS benefit in Non-squamous patients (HR 0.69) Asian Subset (ITT, n=488) Double 2-year and 3-year OS rate ITT mOS Mo [95% CI] ORR DOR

  7. Slide 7: DUBLIN-3 Study Asian Subset Safety (>=10%) TEAE

    Term DUBLIN-3 Study Asian Subset Safety (>=10%) TEAE D group (n=244) DP group (n=240) Preferred term All grades Grade 3 Grade 4 All grades Grade 3 Grade 4 At least one AEs 242(99.2%) 71(29.1%) 107(43.9%) 239(99.6%) 126(52.5%) 43(17.9%) Anaemia 116(47.5%) 13(5.3%) 0(0.0%) 124(51.7%) 11(4.6%) 0(0.0%)

  8. Slide 8: Conclusion

    Conclusion Plinabulin + Docetaxel with durable anti-cancer benefit and significantly reduced severe neutropenia; a potential practice-changing treatment for 2/3L non-squamous NSCLC, EGFR WT The addition of Plinabulin as a single agent added to SOC Docetaxel led to improved anti-cancer efficacy, in t

  9. Slide 9: Acknowledgements

    Acknowledgements • We would like to thank all the patients and their families for their participation and essential role in the study. • We would also like to thank all the investigators and medical staff from 58 sites in the US, China, and Australia and the study team for their contribution to the

BeyondSpring — Technical Presentation (December 2025) on 6ix